Weusten Jos, Hu Jianfang
Center for Mathematical Sciences, MSD, Oss, The Netherlands.
Nonclinical Statistics, Pfizer, Collegeville, Pennsylvania, USA.
Pharm Stat. 2025 Jan-Feb;24(1):e2380. doi: 10.1002/pst.2380. Epub 2024 Apr 11.
In pharmaceutical manufacturing, especially biologics and vaccines manufacturing, emphasis on speedy process development can lead to inadequate process development, which often results in less robust commercial manufacturing process after launch. Process performance index (Ppk) is a statistical measurement of the ability of a process to produce output within specification limits over a period of time. In biopharmaceutical manufacturing, progression in process development is based on Critical Quality Attributes meeting their specification limits, lacking insight into the process robustness. Ppk is typically estimated after 15-30 commercial batches at which point it may be too late/too complex to make process adjustments to enhance robustness. The use of Bayesian statistics, prior knowledge, and input from Subject matter experts (SMEs) offers an opportunity to make predictions on process capability during the development cycle. Developing a standard methodology to assess long term process capability at various stages of development provides several benefits: provides opportunity for early insight into process vulnerabilities thereby enabling resolution pre-licensure; identifies area of the process to prioritize and focus on during process development/process characterization (PC) using a data-driven approach; and ultimately results in higher process robustness/process knowledge at launch. We propose a Bayesian-based method to predict the performance of a manufacturing process at full manufacturing scale during the development and commercialization phase, before commercial data exists. Under Bayesian framework, limited development data for the process of interest at hand, data from similar products, general SME knowledge, and literature can be carefully formulated into informative priors. The implementation of the proposed approach is presented through two examples. To allow for continuous improvement during process development, we recommend to embed this approach of using predictive Ppk at pre-defined commercialization stage-gates, for example, at completion of process development, prior to and completion of PC, prior to technology transfer runs (Engineering/Process Performance Qualification, PPQ), and prior to commercial specification setting.
在制药生产中,尤其是生物制品和疫苗生产中,过于强调快速的工艺开发可能会导致工艺开发不足,这往往会导致产品上市后商业化生产工艺的稳健性较差。过程性能指数(Ppk)是衡量一个过程在一段时间内生产出符合规格限度的产品的能力的统计指标。在生物制药生产中,工艺开发的进展基于关键质量属性符合其规格限度,而缺乏对工艺稳健性的深入了解。Ppk通常在15至30个商业批次之后进行估算,此时进行工艺调整以提高稳健性可能为时已晚或过于复杂。使用贝叶斯统计、先验知识以及主题专家(SME)的意见,为在开发周期内预测工艺能力提供了机会。开发一种在不同开发阶段评估长期工艺能力的标准方法有诸多益处:能提供早期洞察工艺薄弱环节的机会,从而在获批前解决问题;使用数据驱动的方法确定工艺开发/工艺表征(PC)过程中需要优先考虑和关注的工艺领域;最终在产品上市时实现更高的工艺稳健性/工艺知识水平。我们提出一种基于贝叶斯的方法,用于在开发和商业化阶段、在商业数据存在之前预测全规模生产过程的性能。在贝叶斯框架下,可以将手头感兴趣的工艺的有限开发数据、来自类似产品的数据、SME的一般知识以及文献仔细整合为信息性先验。通过两个例子展示了所提方法的实施过程。为了在工艺开发过程中实现持续改进,我们建议在预定义的商业化阶段关卡嵌入这种使用预测性Ppk的方法,例如,在工艺开发完成时、在PC之前和完成时、在技术转移运行(工程/工艺性能确认,PPQ)之前以及在商业规格设定之前。